NCT02629744View on ClinicalTrials.gov

A Study to Evaluate Pain, Tolerability, Safety, and Usability of a Single Self-administered Etrolizumab by Auto-injector in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
Healthy Volunteer
Interventions
DRUG

Etrolizumab

Single SC dose of etrolizumab at 105 milligrams (mg) on Day 1.

DEVICE

Prefilled Auto-injector (Rotaject)

Participants self-administered etrolizumabSC injection using a prefilled auto-injector.

Trial Locations (2)

75247

Dallas

90630

Cypress

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY

NCT02629744 - A Study to Evaluate Pain, Tolerability, Safety, and Usability of a Single Self-administered Etrolizumab by Auto-injector in Healthy Participants | Biotech Hunter | Biotech Hunter